Lipoprotein(a) in Chronic Renal Disease

Peter Stenvinkel, Lars Berglund

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Atherosclerotic vascular disease is a major cause of morbidity and mortality in patients with chronic renal disease and in renal transplant recipients. Epidemiological studies have shown that a high lipoprotein(a) [Lp(a)] concentration in the general population is an independent risk factor for the development of atherosclerotic complications, such as coronary heart disease. Interestingly, plasma levels of Lp(a) have often been reported to be elevated in chronic renal disease. Recent studies have found no difference in the isoform distribution of apo(a) between healthy subjects and patients with renal disease, suggesting that factors other than genetic differences are involved in the high levels of Lp(a) reported in chronic renal disease. In particular, patients with major losses of protein in urine and/or dialysate, such as nephrotic patients and those treated with continuous ambulatory peritoneal dialysis, have been reported to have elevated plasma Lp(a) levels. The results regarding plasma Lp(a) levels in hemodialysis patients are conflicting, although recent evidence suggests that serum albumin levels are of importance for the prevailing Lp(a) levels. In renal transplant recipients conflicting data regarding plasma Lp(a) levels have also been reported, a finding that may be attributable to posttransplant urinary protein losses and/or different immunosuppressive regimens. The importance of Lp(a) as a risk factor for atherosclerotic disease in patients with chronic renal failure remains to established, and prospective evaluations of the role of Lp(a) are necessary.

Original languageEnglish (US)
Pages (from-to)16-21
Number of pages6
JournalMineral and Electrolyte Metabolism
Volume22
Issue number1-3
StatePublished - 1996
Externally publishedYes

Fingerprint

Lipoprotein(a)
Chronic Renal Insufficiency
Plasmas
Transplants
Kidney
Dialysis
Continuous Ambulatory Peritoneal Dialysis
Dialysis Solutions
Immunosuppressive Agents
Vascular Diseases
Serum Albumin
Chronic Kidney Failure
Coronary Disease
Renal Dialysis
Epidemiologic Studies
Healthy Volunteers
Protein Isoforms
Proteins
Urine
Morbidity

Keywords

  • Continuous ambulatory peritoneal dialysis
  • Hemodialysis
  • Lipoprotein(a)
  • Nephrotic syndrome
  • Renal transplant recipients

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Lipoprotein(a) in Chronic Renal Disease. / Stenvinkel, Peter; Berglund, Lars.

In: Mineral and Electrolyte Metabolism, Vol. 22, No. 1-3, 1996, p. 16-21.

Research output: Contribution to journalArticle

Stenvinkel, Peter ; Berglund, Lars. / Lipoprotein(a) in Chronic Renal Disease. In: Mineral and Electrolyte Metabolism. 1996 ; Vol. 22, No. 1-3. pp. 16-21.
@article{5155199b1fff4229857ae400dc82d726,
title = "Lipoprotein(a) in Chronic Renal Disease",
abstract = "Atherosclerotic vascular disease is a major cause of morbidity and mortality in patients with chronic renal disease and in renal transplant recipients. Epidemiological studies have shown that a high lipoprotein(a) [Lp(a)] concentration in the general population is an independent risk factor for the development of atherosclerotic complications, such as coronary heart disease. Interestingly, plasma levels of Lp(a) have often been reported to be elevated in chronic renal disease. Recent studies have found no difference in the isoform distribution of apo(a) between healthy subjects and patients with renal disease, suggesting that factors other than genetic differences are involved in the high levels of Lp(a) reported in chronic renal disease. In particular, patients with major losses of protein in urine and/or dialysate, such as nephrotic patients and those treated with continuous ambulatory peritoneal dialysis, have been reported to have elevated plasma Lp(a) levels. The results regarding plasma Lp(a) levels in hemodialysis patients are conflicting, although recent evidence suggests that serum albumin levels are of importance for the prevailing Lp(a) levels. In renal transplant recipients conflicting data regarding plasma Lp(a) levels have also been reported, a finding that may be attributable to posttransplant urinary protein losses and/or different immunosuppressive regimens. The importance of Lp(a) as a risk factor for atherosclerotic disease in patients with chronic renal failure remains to established, and prospective evaluations of the role of Lp(a) are necessary.",
keywords = "Continuous ambulatory peritoneal dialysis, Hemodialysis, Lipoprotein(a), Nephrotic syndrome, Renal transplant recipients",
author = "Peter Stenvinkel and Lars Berglund",
year = "1996",
language = "English (US)",
volume = "22",
pages = "16--21",
journal = "Mineral and Electrolyte Metabolism",
issn = "0378-0392",
publisher = "S. Karger AG",
number = "1-3",

}

TY - JOUR

T1 - Lipoprotein(a) in Chronic Renal Disease

AU - Stenvinkel, Peter

AU - Berglund, Lars

PY - 1996

Y1 - 1996

N2 - Atherosclerotic vascular disease is a major cause of morbidity and mortality in patients with chronic renal disease and in renal transplant recipients. Epidemiological studies have shown that a high lipoprotein(a) [Lp(a)] concentration in the general population is an independent risk factor for the development of atherosclerotic complications, such as coronary heart disease. Interestingly, plasma levels of Lp(a) have often been reported to be elevated in chronic renal disease. Recent studies have found no difference in the isoform distribution of apo(a) between healthy subjects and patients with renal disease, suggesting that factors other than genetic differences are involved in the high levels of Lp(a) reported in chronic renal disease. In particular, patients with major losses of protein in urine and/or dialysate, such as nephrotic patients and those treated with continuous ambulatory peritoneal dialysis, have been reported to have elevated plasma Lp(a) levels. The results regarding plasma Lp(a) levels in hemodialysis patients are conflicting, although recent evidence suggests that serum albumin levels are of importance for the prevailing Lp(a) levels. In renal transplant recipients conflicting data regarding plasma Lp(a) levels have also been reported, a finding that may be attributable to posttransplant urinary protein losses and/or different immunosuppressive regimens. The importance of Lp(a) as a risk factor for atherosclerotic disease in patients with chronic renal failure remains to established, and prospective evaluations of the role of Lp(a) are necessary.

AB - Atherosclerotic vascular disease is a major cause of morbidity and mortality in patients with chronic renal disease and in renal transplant recipients. Epidemiological studies have shown that a high lipoprotein(a) [Lp(a)] concentration in the general population is an independent risk factor for the development of atherosclerotic complications, such as coronary heart disease. Interestingly, plasma levels of Lp(a) have often been reported to be elevated in chronic renal disease. Recent studies have found no difference in the isoform distribution of apo(a) between healthy subjects and patients with renal disease, suggesting that factors other than genetic differences are involved in the high levels of Lp(a) reported in chronic renal disease. In particular, patients with major losses of protein in urine and/or dialysate, such as nephrotic patients and those treated with continuous ambulatory peritoneal dialysis, have been reported to have elevated plasma Lp(a) levels. The results regarding plasma Lp(a) levels in hemodialysis patients are conflicting, although recent evidence suggests that serum albumin levels are of importance for the prevailing Lp(a) levels. In renal transplant recipients conflicting data regarding plasma Lp(a) levels have also been reported, a finding that may be attributable to posttransplant urinary protein losses and/or different immunosuppressive regimens. The importance of Lp(a) as a risk factor for atherosclerotic disease in patients with chronic renal failure remains to established, and prospective evaluations of the role of Lp(a) are necessary.

KW - Continuous ambulatory peritoneal dialysis

KW - Hemodialysis

KW - Lipoprotein(a)

KW - Nephrotic syndrome

KW - Renal transplant recipients

UR - http://www.scopus.com/inward/record.url?scp=0029655606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029655606&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 16

EP - 21

JO - Mineral and Electrolyte Metabolism

JF - Mineral and Electrolyte Metabolism

SN - 0378-0392

IS - 1-3

ER -